Last reviewed · How we verify
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA (TOCIAION)
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains. Subcutaneous tocilizumab, a targeted biotherapy, recently received marketing authorization for the treatment of GCA, but only demonstrated at yet that it can allow steroid dose sparing. The aim of this study is to assess the benefit of tocilizumab and IV steroids combination or IV steroids alone, in the treatment of AION due to GCA.
Details
| Lead sponsor | Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 58 |
| Start date | Thu Sep 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Dec 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Giant Cell Arteritis
- Optic Ischaemic Neuropathy
Interventions
- tocilizumab and IV steroids combination
- IV steroids combination alone
Countries
France